China has one of the most rapidly growing pharmaceutical markets in the world, as well as a vast, rapidly expanding prevalent population of colorectal cancer (CRC) patients. Combined with increasing access to medical care and a burgeoning middle class with growing economic clout, these factors promise fast growth and significant opportunity for multinational pharmaceutical companies.
Market Covered: China.
Primary research: A total of 90 oncologists surveyed in Beijing, Shanghai, and Guangzhou. Separate in-depth interviews with 8 medical experts.
Epidemiology: Prevalence of CRC: total diagnosed incident cases in urban and rural China. Ten-year epidemiology forecasts through 2022.
Market forecast features: Our analysis evaluates the size of the population receiving drug treatment. We include a detailed forecast for CRC drug classes and leading brands for 2012-2017 using a combination of historical trend analysis and an epidemiology-based, bottom-up market model.